Ericsson A - Search Results

1

A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease.

Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundbäck B, Donaldson GC, Sullivan SD. Borg S, et al. Among authors: ericsson a. Value Health. 2004 Mar-Apr;7(2):153-67. doi: 10.1111/j.1524-4733.2004.72318.x. Value Health. 2004. PMID: 15164805 Free article.

2

Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort.

Gerdtham UG, Andersson LF, Ericsson A, Borg S, Jansson SA, Rönmark E, Lundbäck B. Gerdtham UG, et al. Among authors: ericsson a. Eur J Health Econ. 2009 May;10(2):217-26. doi: 10.1007/s10198-008-0121-6. Epub 2008 Oct 14. Eur J Health Econ. 2009. PMID: 18853206

3

The costs of exacerbations in chronic obstructive pulmonary disease (COPD).

Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prütz C, Rönmark E, Lundbäck B. Andersson F, et al. Among authors: ericsson a. Respir Med. 2002 Sep;96(9):700-8. doi: 10.1053/rmed.2002.1334. Respir Med. 2002. PMID: 12243316 Free article.

4

Costs of COPD in Sweden according to disease severity.

Jansson SA, Andersson F, Borg S, Ericsson A, Jönsson E, Lundbäck B. Jansson SA, et al. Among authors: ericsson a. Chest. 2002 Dec;122(6):1994-2002. doi: 10.1378/chest.122.6.1994. Chest. 2002. PMID: 12475838

5

Cost differences for COPD with and without physician-diagnosis.

Jansson SA, Lindberg A, Ericsson A, Borg S, Rönmark E, Andersson F, Lundbäck B. Jansson SA, et al. Among authors: ericsson a. COPD. 2005 Dec;2(4):427-34. doi: 10.1080/15412550500346501. COPD. 2005. PMID: 17147008 Free article.

6

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.

Löfdahl CG, Ericsson A, Svensson K, Andreasson E. Löfdahl CG, et al. Among authors: ericsson a. Pharmacoeconomics. 2005;23(4):365-75. doi: 10.2165/00019053-200523040-00006. Pharmacoeconomics. 2005. PMID: 15853436

7

Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.

Ericsson Å, Lundqvist A. Ericsson Å, et al. Appl Health Econ Health Policy. 2017 Apr;15(2):237-248. doi: 10.1007/s40258-016-0301-y. Appl Health Econ Health Policy. 2017. PMID: 28063135 Free PMC article.

8

Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden.

Andersson E, Persson S, Hallén N, Ericsson Å, Thielke D, Lindgren P, Steen Carlsson K, Jendle J. Andersson E, et al. Among authors: ericsson a. Diabetologia. 2020 Dec;63(12):2582-2594. doi: 10.1007/s00125-020-05277-3. Epub 2020 Sep 24. Diabetologia. 2020. PMID: 32968866 Free PMC article.

9

Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.

Eliasson B, Ericsson Å, Fridhammar A, Nilsson A, Persson S, Chubb B. Eliasson B, et al. Among authors: ericsson a. Pharmacoecon Open. 2022 May;6(3):343-354. doi: 10.1007/s41669-021-00317-z. Epub 2022 Jan 21. Pharmacoecon Open. 2022. PMID: 35064550 Free PMC article.

10

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.

Jendle J, Ericsson Å, Ekman B, Sjöberg S, Gundgaard J, da Rocha Fernandes J, Mårdby AC, Hunt B, Malkin SJP, Thunander M. Jendle J, et al. Among authors: ericsson a. J Med Econ. 2020 Nov;23(11):1311-1320. doi: 10.1080/13696998.2020.1805454. Epub 2020 Sep 14. J Med Econ. 2020. PMID: 32746676 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

408 results

Search Page

Filters